Targeted inhibition of Notch1 gene enhances the killing effects of Paclitaxel on triple-negative breast cancer cells

Objective:To study the influence of targeted inhibition of Notch1 gene on the killing effects of Paclitaxel on triple-negative breast cancer cells.Methods:The triple-negative [estrogen receptor(ER)/progesterone receptor(PR)/human epidermal growth factor receptor 2(Her2)] breast cancer cell line MDA-MB-231 and ER/PR/HER-2-positive breast cancer cell line MCF-7 were cultured,transfected with Notch1-si RNA-overexpression plasmid and blank plasmid,and treated with different concentrations of paclitaxel,and then the cell proliferation activity and apoptosis rate as well as the m RNA expression of Caspase-3,Caspase-9 and Bcl-2 were determined.Results:Paclitaxel could decrease the MDA-MB-231 and MCF-7 cell proliferation activity as well as Bcl-2 mRNA expression,and increase MDA-MB-231 and MCF-7 cell apoptosis rate as well as Caspase-3 and Caspase-9 mRNA expression in dosedependent manners;with the same dose of paclitaxel treatment,the inhibitory effects on MDAMB-231 cell proliferation activity and Bcl-2 m RNA expression as well as the promoting effects on MDA-MB-231 cell apoptosis and mR NA expression of Caspase-3 and Caspase-9 were weaker than those on MCF-7 cell;after 0.5 μM paclitaxel combined with Notch1-siRNA treatment,MDA-MB-231 cell proliferation activity and Bcl-2 mRNA expression were significantly lower than those after 0.5 μM paclitaxel combined with control plasmid treatment while cell apoptosis rate and mR NA expression of Caspase-3 and Caspase-9 were higher than those after 0.5 μM paclitaxel combined with control plasmid treatment.Conclusions:Targeted inhibition of Notch1 gene may enhance the killing effects of paclitaxel on triple-negative breast cancer cells by up-regulating the expression of Caspase-3 and Caspase-9 and inhibiting the expression of Bcl-2.

Effect of Qingre Yangyin Humo prescription on serum indexes in esophageal cancer radiotherapy

Objective:To study the effectiveness of Qingre Yangyin Humo prescription in preventing radioaction esophagitis and its effect on the serum radiation damage indexes.Methods:Patients with advanced esophageal cancer who received radiotherapy in the First Affiliated Hospital of Bengbu Medical College between June 2015 and December 2016 were selected as the research subjects and randomly divided into two groups, the intervention group received Qingre Yangyin Humo prescription during radiotherapy, and the control group received regular intervention during radiotherapy. The incidence of radiation esophagitis within 90 days after radiotherapy was observed, and serum inflammation indexes, oxidative stress indexes and pulmonary fibrosis index were determined before radiotherapy as well as 2 weeks and 4 weeks after radiotherapy.Results: After radiotherapy, serum TNF-α, IL-1β, IL-6, IL-8, MDA, 8-OHdG, MMP9, TGF-β1 and ACE levels of both groups were significantly higher than those before radiotherapy while GPX1, T-SOD and Mn-SOD levels were significantly lower than those before radiotherapy, and serum TNF-α, IL-1β, IL-6, IL-8, MDA, 8-OHdG, MMP9, TGF-β1 and ACE levels of intervention group were significantly lower than those of control group while GPX1, T-SOD and Mn-SOD levels were significantly higher than those of control group.Conclusion:Qingre Yangyin Humo prescription can prevent the occurrence of radiation esophagitis and reduce radiation damage during radiotherapy.